DexCom v. Abbott: Federal Circuit CGM Patent Appeal Dismissed After 663 Days
DexCom, Inc. moved to voluntarily dismiss its Federal Circuit appeal against Abbott Laboratories over US10702215B2, a patent covering intelligent glycemic alert monitoring systems. The court granted the motion under Fed. R. App. P. 42(b), with each side bearing its own costs — leaving the underlying patentability dispute unresolved on the merits.
DexCom’s Federal Circuit CGM appeal ends without a merits decision
DexCom, Inc. filed this appeal at the Court of Appeals for the Federal Circuit on 5 January 2024, challenging a patentability determination relating to US10702215B2. That patent covers systems and methods for dynamically and intelligently monitoring a host’s glycemic condition after an alert is triggered — a core function in continuous glucose monitoring (CGM) wearable devices. Abbott Laboratories, a principal rival in the CGM market, was the respondent.
The appeal concluded on 29 October 2025 when DexCom itself moved to dismiss under Fed. R. App. P. 42(b), the Federal Rules of Appellate Procedure provision governing voluntary dismissals at the appellate level. The Federal Circuit granted the motion. Critically, no merits ruling was issued: the underlying patentability question — whether the claims of US10702215B2 are valid — remains formally unanswered by this proceeding. Each side was ordered to bear its own costs, consistent with the 42(b) motion’s terms.
At 663 days, the case ran substantially through the typical Federal Circuit appeal window before DexCom elected to withdraw — a timeline that suggests significant briefing activity or parallel proceedings may have influenced the decision. The public record does not disclose whether a settlement, licensing arrangement, or strategic reassessment drove the dismissal. What is clear is that the patent’s enforceability landscape remains uncertain: no appellate court has affirmed or invalidated the claims at issue.
Filing to Appeal Dismissed in 663 days
663 days — longer than the median Federal Circuit appeal lifecycle, suggesting protracted pre-dismissal activity
Appeal dismissed under Rule 42(b): what the procedural exit means for both parties
Rule 42(b) dismissal: the appellant walks away before a ruling
Fed. R. App. P. 42(b) allows an appellant to voluntarily dismiss an appeal by motion, with the court’s approval. Here, DexCom — the party that brought the appeal — filed the motion itself. The Federal Circuit granted it without reaching the merits of the patentability dispute. This is a procedural exit, not an adjudication: no court has ruled on whether US10702215B2 is valid or invalid at the appellate level.
No merits ruling issuedDexCom’s patent status: neither vindicated nor invalidated
Because the Federal Circuit dismissed without reaching the merits, DexCom neither won nor lost on the patentability question. The patent remains in its pre-appeal state — whatever the underlying tribunal determined still stands as the operative ruling. DexCom retains the right to enforce US10702215B2 in future proceedings, but the voluntary dismissal may reflect a strategic recalibration rather than confidence in the patent’s strength.
Patent status unchanged on appealAbbott avoids an adverse appellate ruling — for now
Abbott Laboratories benefits from the absence of a merits ruling: no Federal Circuit precedent was set that could strengthen DexCom’s patent position. Each side bearing its own costs suggests no clear prevailing party. Abbott’s freedom to operate in the dynamic glycemic alert monitoring space is not formally clarified by this outcome, but the dismissal removes an immediate appellate threat and preserves Abbott’s litigation optionality going forward.
No appellate precedent setCGM sector uncertainty persists around this patent family
The DexCom–Abbott CGM rivalry is one of the most commercially significant in wearable medical technology. A voluntary dismissal at this stage — without merits resolution — leaves the validity of US10702215B2’s claims unconfirmed for the broader market. Competitors developing post-alert glycemic monitoring systems should treat this patent as an active risk requiring FTO analysis. The dismissal does not preclude DexCom from re-asserting the patent in district court or alternative proceedings.
Patent remains an active commercial riskFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | DexCom, Inc. | Company | Continuous glucose monitoring technology company — holder of US10702215B2Search in Eureka ↗ |
| Defendant | Abbott Laboratories, Inc. | Company | Abbott Laboratories, Inc. — diversified medical device and diagnostics company, CGM market competitorSearch in Eureka ↗ |
| Plaintiff counsel | Adam R. Wichman | Attorney | Counsel for DexCom, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Anant Kumar Saraswat | Attorney | Counsel for DexCom, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Elisabeth H. Hunt | Attorney | Counsel for DexCom, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Nathan R. Speed | Attorney | Counsel for DexCom, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Richard F. Giunta | Attorney | Counsel for DexCom, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Wolf Greenfield & Sacks PC | Law Firm | Representing DexCom, Inc.Search in Eureka ↗ |
| Defendant counsel | Eliot Damon Williams | Attorney | Counsel for Abbott Laboratories, Inc.Search in Eureka ↗ |
| Defendant law firm | Baker Botts LLP | Law Firm | Representing Abbott Laboratories, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s order is strictly procedural: DexCom’s Rule 42(b) motion was granted without any substantive engagement with the patentability merits. The phrasing ‘each side to bear its own costs’ is standard for voluntary appellate dismissals and does not indicate relative strength of either party’s position. No claim construction, validity finding, or precedential statement was issued. The underlying patentability determination from the originating tribunal — whether inter partes review or district court — remains the operative record. Practitioners should note that this outcome creates no res judicata bar on future DexCom enforcement of US10702215B2.
US10702215B2 — Dynamic glycemic condition monitoring after alert trigger
US10702215B2, filed under application number US16/674979, protects systems and methods for dynamically and intelligently monitoring a host’s glycemic condition after a glucose alert has been triggered. The patent sits at the intersection of biosensor hardware, real-time data processing, and adaptive algorithm logic — a technically complex claim space that covers not just the sensor itself but the responsive intelligence layer that activates following a clinical alert event. This places it squarely within the competitive core of next-generation CGM system design.
In the CGM market — where DexCom and Abbott (Libre platform) compete directly for clinical and consumer share — patents covering alert-response logic represent a meaningful competitive differentiator. As CGM devices become embedded in diabetes management protocols, hospital systems, and consumer wellness applications, the post-alert monitoring layer becomes increasingly important to patient outcomes and device differentiation. Any company developing CGM firmware, alert algorithms, or glycemic management software should treat this patent as a material risk asset until its validity is conclusively resolved.
Should you run an FTO against US10702215B2?
Any R&D team developing continuous glucose monitoring systems, post-alert glycemic response algorithms, or adaptive CGM firmware should conduct a freedom-to-operate assessment against US10702215B2. The patent’s claim scope — centred on dynamic, intelligent monitoring following a glucose alert trigger — is broad enough to implicate software-defined responses, threshold-based escalation logic, and condition-adaptive data display. The absence of a definitive Federal Circuit validity ruling means the patent cannot be assumed invalid or design-arounded without rigorous claim analysis.
PatSnap Eureka’s FTO Search Agent enables IP and R&D teams to map US10702215B2 claims against their own technology stack, identify prior art that may support invalidity arguments, and benchmark their product features against the patent’s claim language. Eureka can also surface related continuation applications and DexCom’s broader CGM portfolio, giving product teams a full picture of enforcement risk before launch or investment decisions are made.
Run a freedom-to-operate analysis on US10702215B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit CGM and biosensor patent appeal cases
Cases involving continuous glucose monitoring patents at the Federal Circuit, including patentability challenges and voluntary dismissals in the wearable diagnostics sector.
What this case signals for the CGM and wearable diagnostics IP landscape
A voluntary Federal Circuit dismissal between two CGM market leaders leaves patent validity unresolved — and enforcement risk live.
Voluntary appellate dismissals do not extinguish patent risk
DexCom’s Rule 42(b) exit means US10702215B2 is neither confirmed valid nor invalidated at the Federal Circuit level. Companies developing continuous glucose monitoring or post-alert response systems cannot treat this dismissal as a clearance event. The patent remains potentially enforceable and should be evaluated in any FTO assessment covering dynamic glycemic monitoring technology.
Cost symmetry signals possible negotiated resolution outside the record
When each party bears its own costs in a voluntary appellate dismissal, it is consistent with — though does not confirm — an out-of-court resolution such as a licensing agreement or cross-licensing arrangement. IP professionals tracking the DexCom–Abbott competitive dynamic should monitor subsequent patent filings, licensing disclosures, and product launches for signals of how the underlying dispute was resolved commercially.
DexCom v Abbott — key questions answered
DexCom filed an appeal at the Federal Circuit on 5 January 2024 concerning patentability of US10702215B2. On 29 October 2025, DexCom moved to voluntarily dismiss the appeal under Fed. R. App. P. 42(b). The Federal Circuit granted the motion, with each side bearing its own costs. No merits ruling was issued.
No. A voluntary dismissal under Rule 42(b) is a procedural exit — it does not constitute an appellate ruling on the validity or invalidity of US10702215B2. The patent remains in whatever validity state was determined by the originating tribunal. DexCom retains enforcement rights unless and until a court rules the patent invalid.
When an appellate dismissal orders each side to bear its own costs, it means neither party is entitled to recover appellate litigation costs from the other. This is a standard term in voluntary Rule 42(b) dismissals and does not indicate which party held the stronger position. It is consistent with — but does not confirm — a negotiated resolution between the parties.
US10702215B2 covers systems and methods for dynamically and intelligently monitoring a host’s glycemic condition after a glucose alert has been triggered. It addresses the adaptive, responsive monitoring layer in continuous glucose monitoring (CGM) devices — specifically how the device or system behaves following a clinical glucose alert event. This is commercially relevant to both DexCom and Abbott’s Libre CGM platforms.
Yes. A voluntary appellate dismissal does not create a res judicata bar on future enforcement. DexCom may assert US10702215B2 in district court infringement actions or other proceedings. The dismissal removes this specific Federal Circuit appeal from the record but does not limit DexCom’s broader enforcement options. Competitors in the CGM space should continue to treat the patent as an active enforcement risk.
PatSnap Eureka searches patents and litigation data to answer instantly.